Abstract
The worldwide COVID-19 pandemic has had devastating effects on health, healthcare infrastructure, social structure, and economics. One of the limiting factors in containing the spread of this virus has been the lack of widespread availability of fast, inexpensive, and reliable methods for testing of individuals. Frequent screening for infected and often asymptomatic people is a cornerstone of pandemic management plans. Here, we introduce two pH sensitive ‘LAMPshade’ dyes as novel readouts in an isothermal RT-LAMP amplification assay for SARS-CoV-2 RNA. The resulting JaneliaLAMP (jLAMP) assay is robust, simple, inexpensive, has low technical requirements and we describe its use and performance in direct testing of contrived and clinical samples without RNA extraction.
Introduction
The COVID-19 pandemic highlighted a critical vulnerability in global healthcare: the reliance on centralized, resource-intensive diagnostic testing. Quantitative RT-PCR (qRT-PCR), while the "gold standard" for sensitivity, requires sophisticated thermal cyclers, specialized reagents, and time-consuming RNA extraction steps. These requirements create bottlenecks that lead to long turnaround times and supply chain vulnerabilities, hindering the rapid screening necessary for effective pandemic management.
To address these challenges, researchers at Janelia Research Campus developed JaneliaLAMP (jLAMP), an isothermal amplification assay designed for speed, simplicity, and cost-effectiveness. By utilizing novel pH-sensitive dyes and an extraction-free protocol, jLAMP offers a viable "point-of-care" (POC) alternative for frequent surveillance.
The Innovation: LAMPshade Dyes
The core innovation of jLAMP lies in the introduction of two novel pH-sensitive dyes: LAMPshade Magenta and LAMPshade Violet. Traditional RT-LAMP (Reverse Transcription Loop-mediated Isothermal Amplification) assays often rely on Phenol Red as a pH indicator. Phenol Red transitions from red to yellow as the pH drops during DNA synthesis, but this transition is often shallow and can be ambiguous, particularly for colorblind individuals or when clinical samples have varying baseline acidities.
In contrast, the LAMPshade dyes are engineered with a pKa (7.08–7.48) perfectly tuned to the pH swing of a LAMP reaction (which typically moves from ~8.5 down to ~6.0). These dyes exhibit a "cooperative transition," switching sharply from a highly colored state to colorless as the reaction progresses. This results in a clear, binary (on/off) visual readout that removes the guesswork inherent in ratiometric dyes. Additionally, these dyes support a dual readout, functioning for both visual inspection and fluorescence-based detection using UV light or plate readers.
Methods and Workflow
The jLAMP assay is designed to be performed with minimal equipment, requiring only a simple heat source maintained at 60°C.
Extraction-Free Protocol
A significant barrier to rapid testing is the RNA extraction process. jLAMP bypasses this by employing a "direct" testing workflow. Instead of purifying RNA, raw samples—such as nasopharyngeal swab media or saline—are heat-treated to inactivate the virus and release the RNA. This treated sample is then added directly to the jLAMP master mix, significantly reducing the time and technical expertise required.
Validation Datasets
The study validated the assay using several sample types:
- Contrived Samples: Heat-inactivated SARS-CoV-2 spiked into various media (UTM, VTM, and saline).
- Clinical Samples: 60 nasopharyngeal (NP) swab samples (30 positive, 30 negative) previously characterized by qRT-PCR.
- Specificity Panels: A respiratory control panel including influenza, adenovirus, and other coronaviruses to ensure no cross-reactivity.
- Integrity Controls: Human cell lines (HEK293) were used to validate internal primers (RPP30 and 18S rRNA), ensuring the sample contained sufficient human material for a valid test.
Key Results and Performance
The jLAMP assay provides results in under an hour at an estimated cost of approximately $2.88 per sample for disposable components.
- Sensitivity: The 95% Limit of Detection (LoD) was determined to be 22.6 RNA copies per assay in saline and 90.6 copies in Universal Transport Media (UTM).
- Clinical Accuracy: In head-to-head testing with clinical samples, jLAMP successfully detected 23 out of 30 positive samples. The samples missed were primarily those with extremely low viral loads (Ct > 36), which are generally considered below the threshold for high transmissibility.
- Specificity: The assay showed zero cross-reactivity with common respiratory pathogens, though it does detect the original 2003 SARS-CoV due to high genetic homology.
- Stability: The master mix remained stable at -20°C for at least four weeks without complex cryoprotectants, making it viable for deployment in resource-limited settings.
Discussion: Surveillance vs. Clinical Diagnosis
A key insight of this work is the distinction between clinical diagnosis and surveillance testing. While jLAMP is less sensitive than extracted PCR, it is highly effective for surveillance. Individuals with transmissible levels of the virus typically possess >10,000 copies/µL. Because jLAMP reliably catches anything above 100 copies/µL, it is more than sufficient to identify infectious individuals and stop the spread.
Limitations and Future Work
While robust, the assay faces some limitations. Universal Transport Media (UTM) was found to be somewhat inhibitory compared to saline, slightly reducing sensitivity. Furthermore, while preliminary results with saliva were promising, the high variability of saliva between individuals suggests that some samples might still require simplified RNA purification to prevent false positives. Future work will focus on scaling the chemistry for high-throughput, real-world POC settings and further optimizing saliva-based protocols.
Summary updated